Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan Receives Approval for Tizanidine Hydrochloride Tablets
Mylan Receives Approval for Tizanidine Hydrochloride Tablets PITTSBURGH--(BUSINESS WIRE)--April 1, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application for Tizanidine Hydrochloride Tablets, 2mg and 4
View HTML
Toggle Summary Mylan Announces Resolution of Two Legal Matters
Mylan Announces Resolution of Two Legal Matters PITTSBURGH--(BUSINESS WIRE)--March 31, 2003--Mylan Laboratories Inc. (NYSE: MYL) announced today that it has reached a tentative settlement of the class action lawsuit filed against the Company by the direct purchaser plaintiffs concerning the
View HTML
Toggle Summary Mylan Declares Regular Quarterly Cash Dividend
Mylan Declares Regular Quarterly Cash Dividend PITTSBURGH, Mar 17, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of 3.33 cents per share will be paid on April 15, 2003, to shareholders of record on March 31, 2003.
View HTML
Toggle Summary Mylan Names Prominent Neurosurgeon, Joseph C. Maroon, M.D. to Its Board of Directors
Mylan Names Prominent Neurosurgeon, Joseph C. Maroon, M.D. to Its Board of Directors PITTSBURGH, Feb 26, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that it has named Joseph C. Maroon, M.D., to its Board of Directors. Dr.
View HTML
Toggle Summary Mylan Receives Approval for Tamoxifen Citrate Tablets
Mylan Receives Approval for Tamoxifen Citrate Tablets PITTSBURGH, Feb 21, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Tamoxifen Citrate Tablets USP, 10 mg and 20
View HTML
Toggle Summary Mylan Reaches Final Agreement with Bristol-Myers Squibb
Mylan Reaches Final Agreement with Bristol-Myers Squibb PITTSBURGH, Feb 20, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) today announced that it has reached a final agreement with Bristol-Myers Squibb (BMS), which resolves all disputes between the companies related to buspirone.
View HTML
Toggle Summary Mylan is Granted Summary Judgment on all Three Strengths of Mirtazapine
Mylan is Granted Summary Judgment on all Three Strengths of Mirtazapine PITTSBURGH--(BUSINESS WIRE)--Dec. 20, 2002--Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. District Court for the District of New Jersey has granted summary judgment in Mylan's favor on the issue of
View HTML
Toggle Summary Mylan Laboratories Inc. Announces First ANDA Approval for Isotretinoin; Bertek Pharmaceuticals Inc. to Market Amnesteem
Mylan Laboratories Inc. Announces First ANDA Approval for Isotretinoin; Bertek Pharmaceuticals Inc. to Market Amnesteem PITTSBURGH--(BUSINESS WIRE)--Nov. 11, 2002--Mylan Laboratories Inc. (NYSE: MYL) today announced that the Food and Drug Administration has granted the first Abbreviated New Drug
View HTML
Toggle Summary Mylan Reports Record Second Quarter EPS of $.54
Mylan Reports Record Second Quarter EPS of $.54 Business Editors PITTSBURGH, Oct 29, 2002 (BUSINESS WIRE) -- Financial Highlights - Net revenues increased 12% to $319.5 million - Gross profit increased 2% to $166.7 million - Net earnings increased 6% to $68.2 million - Earnings per diluted share
View HTML
Toggle Summary Mylan Laboratories Inc. Increases Dividend 25%
Mylan Laboratories Inc. Increases Dividend 25% PITTSBURGH, Oct 28, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that at its regularly scheduled meeting, the board of directors declared an annual dividend increase of 25% to $.20 per share.
View HTML